RTA Laboratuvarlari Biyolojik
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, paint… Read more
RTA Laboratuvarlari Biyolojik (RTALB) - Total Liabilities
Latest total liabilities as of June 2025: TL103.51 Million TRY
Based on the latest financial reports, RTA Laboratuvarlari Biyolojik (RTALB) has total liabilities worth TL103.51 Million TRY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
RTA Laboratuvarlari Biyolojik - Total Liabilities Trend (2010–2024)
This chart illustrates how RTA Laboratuvarlari Biyolojik's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
RTA Laboratuvarlari Biyolojik Competitors by Total Liabilities
The table below lists competitors of RTA Laboratuvarlari Biyolojik ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Unictron Technologies Corp
TW:6792
|
Taiwan | NT$447.84 Million |
|
Hyundai E P
KO:089470
|
Korea | ₩317.54 Billion |
|
Youlife Group Inc. American Depositary Shares
NASDAQ:YOUL
|
USA | $1.45 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp261.44 Billion |
|
Toung LoongTextile Mfg Co Ltd
TWO:4401
|
Taiwan | NT$3.04 Billion |
|
Powerwell Holdings Bhd
KLSE:0217
|
Malaysia | RM68.20 Million |
|
Kortek Corporation
KQ:052330
|
Korea | ₩81.00 Billion |
|
Go Hub Capital Berhad
KLSE:0311
|
Malaysia | RM26.11 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down RTA Laboratuvarlari Biyolojik's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RTA Laboratuvarlari Biyolojik's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RTA Laboratuvarlari Biyolojik (2010–2024)
The table below shows the annual total liabilities of RTA Laboratuvarlari Biyolojik from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | TL252.17 Million | +34.30% |
| 2023-12-31 | TL187.77 Million | +74.71% |
| 2022-12-31 | TL107.47 Million | -48.62% |
| 2021-12-31 | TL209.17 Million | +135.77% |
| 2020-12-31 | TL88.72 Million | +673.78% |
| 2019-12-31 | TL11.47 Million | +27.53% |
| 2018-12-31 | TL8.99 Million | +1.68% |
| 2017-12-31 | TL8.84 Million | -17.29% |
| 2016-12-31 | TL10.69 Million | -28.15% |
| 2015-12-31 | TL14.88 Million | +30.52% |
| 2014-12-31 | TL11.40 Million | +33.81% |
| 2013-12-31 | TL8.52 Million | -9.94% |
| 2012-12-31 | TL9.46 Million | +47.52% |
| 2011-12-31 | TL6.41 Million | +18.89% |
| 2010-12-31 | TL5.39 Million | -- |